Senior economist and head of the Department of Economics at UWI St Augustine, Dr Daren Conrad is cautioning that recent backpay disbursements to public-sector workers are unlikely ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...
(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, has announced on Friday a private investment in public equity financing of up to approximately $175 million. The ...
CAMBRIDGE, Mass. - ProMIS Neurosciences Inc. (NASDAQ:PMN) has entered into a securities purchase agreement with institutional and accredited investors to raise up to $175 million through a private ...
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease Clear and near-term value inflection points, with blinded 6-month ...
We changed the address of the Stockhouse website from www.stockhouse.com to stockhouse.com. When this page refreshes you will be logged in with the new address ...
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month ...
Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 ...
Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Cambridge, Massachusetts, Dec. 18, 2025 ...
Hosted on MSN
ProMIS Neurosciences regains Nasdaq compliance
ProMIS Neurosciences ( (PMN)) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ...
ProMIS Neurosciences Inc. (NASDAQ:PMN) announced that its shareholders approved a share consolidation proposal at a special meeting held Monday. According to a statement based on a recent SEC filing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results